Neue Publikationen/new publications:
Ortín, I., Ochoa-Callejero, L., Werner, C., Lindenblatt, D., Niefind, K., Martínez, A., de Pascual-Teresa, B., Ramos, A. (2025). Targeting Casein Kinase 2 and Histone Deacetylase with a Dual Inhibitor Effectively Reduces Tumor Growth in a Triple-Negative Breast Cancer Xenograft Model. ACS Pharmacol. Transl. Sci. 8, 2093-2105.
Niefind, K., Götz, C., Jose, J. (2025). 70 years of CK2: still exciting, essential - and enigmatic! Biol. Chem. 406, 65-67.
Werner, C., Eimermacher, S., Harasimowicz, H., Fischer, D., Pietsch, M., Niefind, K. (2025). A CK2α' mutant indicating why CK2α and CK2α', the isoforms of the catalytic subunit of human protein kinase CK2, deviate in affinity to CK2β. Biol. Chem. 406, 101-115.
Marminon, C., Werner, C., Gast, A., Herfindal, L., Charles, J., Lindenblatt, D., Aichele, D., Mularoni, A., Døskeland, S. O., Jose, J., Niefind, K., Le Borgne, M. (2025). Exploring the biological potential of the brominated indenoindole MC11 and its interaction with protein kinase CK2. Biol. Chem. 406, 125-138.
Rumler, H., Schmithals, C., Werner, C., Bollacke, A., Aichele, D., Götz, C., Niefind, K., Wünsch, B., Jose, J. (2024). Discovery of 7,9-Dibromo-dihydrodibenzofuran as a Potent Casein Kinase 2 (CK2) Inhibitor: Synthesis, Biological Evaluation, and Structural Studies on E-/Z-Isomers. ACS Pharmacol. Transl. Sci. 7, 3846-3866.
